523 related articles for article (PubMed ID: 27737879)
1. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.
Chao T; Furth EE; Vonderheide RH
Cancer Immunol Res; 2016 Nov; 4(11):968-982. PubMed ID: 27737879
[TBL] [Abstract][Full Text] [Related]
2. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
Awaji M; Saxena S; Wu L; Prajapati DR; Purohit A; Varney ML; Kumar S; Rachagani S; Ly QP; Jain M; Batra SK; Singh RK
FASEB J; 2020 Jul; 34(7):9405-9418. PubMed ID: 32453916
[TBL] [Abstract][Full Text] [Related]
3. CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β.
Jablonska J; Wu CF; Andzinski L; Leschner S; Weiss S
Int J Cancer; 2014 Mar; 134(6):1346-58. PubMed ID: 24154944
[TBL] [Abstract][Full Text] [Related]
4. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
5. RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis.
Lesina M; Wörmann SM; Morton J; Diakopoulos KN; Korneeva O; Wimmer M; Einwächter H; Sperveslage J; Demir IE; Kehl T; Saur D; Sipos B; Heikenwälder M; Steiner JM; Wang TC; Sansom OJ; Schmid RM; Algül H
J Clin Invest; 2016 Aug; 126(8):2919-32. PubMed ID: 27454298
[TBL] [Abstract][Full Text] [Related]
6. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
[TBL] [Abstract][Full Text] [Related]
7. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer.
Li A; King J; Moro A; Sugi MD; Dawson DW; Kaplan J; Li G; Lu X; Strieter RM; Burdick M; Go VL; Reber HA; Eibl G; Hines OJ
Am J Pathol; 2011 Mar; 178(3):1340-9. PubMed ID: 21356384
[TBL] [Abstract][Full Text] [Related]
9. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
10. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
11. Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice.
Mei J; Liu Y; Dai N; Hoffmann C; Hudock KM; Zhang P; Guttentag SH; Kolls JK; Oliver PM; Bushman FD; Worthen GS
J Clin Invest; 2012 Mar; 122(3):974-86. PubMed ID: 22326959
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
[TBL] [Abstract][Full Text] [Related]
13. Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
Cui D; Zhao Y; Xu J
Cancer Biol Ther; 2019; 20(5):608-616. PubMed ID: 30404567
[TBL] [Abstract][Full Text] [Related]
14. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
Kaneda MM; Cappello P; Nguyen AV; Ralainirina N; Hardamon CR; Foubert P; Schmid MC; Sun P; Mose E; Bouvet M; Lowy AM; Valasek MA; Sasik R; Novelli F; Hirsch E; Varner JA
Cancer Discov; 2016 Aug; 6(8):870-85. PubMed ID: 27179037
[TBL] [Abstract][Full Text] [Related]
15. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.
Bayne LJ; Beatty GL; Jhala N; Clark CE; Rhim AD; Stanger BZ; Vonderheide RH
Cancer Cell; 2012 Jun; 21(6):822-35. PubMed ID: 22698406
[TBL] [Abstract][Full Text] [Related]
16. The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice.
Hoffman MT; Kemp SB; Salas-Escabillas DJ; Zhang Y; Steele NG; The S; Long D; Benitz S; Yan W; Margolskee RF; Bednar F; Pasca di Magliano M; Wen HJ; Crawford HC
Cell Mol Gastroenterol Hepatol; 2021; 11(2):349-369. PubMed ID: 32882403
[TBL] [Abstract][Full Text] [Related]
17. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Steele CW; Karim SA; Leach JDG; Bailey P; Upstill-Goddard R; Rishi L; Foth M; Bryson S; McDaid K; Wilson Z; Eberlein C; Candido JB; Clarke M; Nixon C; Connelly J; Jamieson N; Carter CR; Balkwill F; Chang DK; Evans TRJ; Strathdee D; Biankin AV; Nibbs RJB; Barry ST; Sansom OJ; Morton JP
Cancer Cell; 2016 Jun; 29(6):832-845. PubMed ID: 27265504
[TBL] [Abstract][Full Text] [Related]
18. Deletion of C-C Motif Chemokine Ligand 5 Worsens Invariant Natural Killer T-Cell-Mediated Hepatitis via Compensatory Up-regulation of CXCR2-Related Chemokine Activity.
Chen L; Gu J; Qian Y; Li M; Qian Y; Xu M; Li J; Wen Y; Xia L; Li J; Xia Q; Kong X; Wu H
Cell Mol Gastroenterol Hepatol; 2019; 7(3):623-639. PubMed ID: 30630119
[TBL] [Abstract][Full Text] [Related]
19. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin.
Cheng Y; Mo F; Li Q; Han X; Shi H; Chen S; Wei Y; Wei X
Mol Cancer; 2021 Apr; 20(1):62. PubMed ID: 33814009
[TBL] [Abstract][Full Text] [Related]
20. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5.
Ando Y; Ohuchida K; Otsubo Y; Kibe S; Takesue S; Abe T; Iwamoto C; Shindo K; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Oda Y; Nakamura M
PLoS One; 2020; 15(1):e0228015. PubMed ID: 31999765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
